ABSTRACT
DRG1 is a highly conserved member of a class of GTPases implicated in ribosome biogenesis and translation. The expression of mammalian DRG1 is elevated in the central nervous system during development, and its function has been implicated in fundamental cellular processes including protein synthesis and cellular proliferation. Using exome sequencing, we identified rare and likely pathogenic germline DRG1 variants including three stop-gained p.Gly54*, p.Arg140*, p.Lys263* and a p.Asn248Phe missense variant. These alleles segregate recessively in four affected individuals from three unrelated families and cause a neurodevelopmental disorder with global developmental delay, microcephaly, short stature and craniofacial anomalies. Using functional assays, we show that these loss-of-function variants: 1) severely disrupt DRG1 mRNA/protein stability in patient-derived fibroblasts, 2) impair it’s GTPase activity in vitro and 3) compromise it’s binding to partner protein ZC3H15. Consistent with the importance of DRG1 in humans, targeted inactivation of Drg1 in mice resulted in pre-weaning lethality. Our work highlights the importance of DRG1 GTPase activity for normal development and underscores the significance of translation factor GTPases in human physiology and homeostasis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.L.C is a Cancer Research UK Fellow. B.R. is an investigator of the National Research Foundation (NRF, Singapore) and Branco Weiss Foundation (Switzerland) and an EMBO Young Investigator. We thank the SRIS Asian Skin Biobank (ASB), especially Alicia YAP Mei Yi, Joycelyn LEE Xiang Yi, and Siti Nur Aishah Binte ALIMAT, for isolating and expanding the primary fibroblasts. The ASB work was funded by the A*STAR IAF-PP Project (H1701a0004). This work was funded by a CRUK Programme Foundation Award to M.L.C. (C33483/A25674), a Strategic Positioning Fund for Genetic Orphan Diseases and an inaugural A*STAR Investigatorship from the Agency for Science, Technology and Research in Singapore to B.R. and the Singhealth Duke-NUS Genomic Medicine Centre Fund (SDDC/FY2021/EX/93-A147). F. P. is a recipient of a long-term European Molecular Biology Organization (EMBO) postdoc fellowship and a short-term EMBO travel fellowship. Her research is supported by the Singapore Ministry of Health National Medical Research Council under its Young Individual Research Grant scheme (Project ID MOH-000549-01) and A*STAR under its Career Development Award (Project number C210112002). A.A.M is a recipient of Sultan Qaboos University Strategic research funding (project code SR/MED/GENT/16/01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved in Oman by the ethics committees of the Medical Research Ethical Committee of the Sultan Qaboos University for Family 1, of KK Women's and Children's Hospital for Family 2, and Centogene (Germany) for Family 3. The parents of each family provided written informed consent to participate in this study and to publish their family pedigrees and clinical data. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. The study protocol was approved by A*STAR institutional review board (IRB 2019-087) and genetic analyses were performed in accordance with bioethics rules of national laws.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding authors upon request.
